

## **PRESS RELEASE**

10 February 2025 16:05:00 CET

## AcouSort reschedules the 2024 year-end report to February 14, 2025

AcouSort AB (publ) ("AcouSort" or the "Company") announces today that the Company is bringing forward its year-end report 2024. The year-end report will be published on Friday, February 14, 2025.

AcouSort's Board of Directors has decided to bring forward the year-end report for 2024 to Friday, February 14, instead of February 26 as previously communicated in the Company's financial calendar. This is because the work on the report will be completed earlier than planned.

## FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

## **ABOUT ACOUSORT**

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).